# Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Canonical URL: https://biopharmsignal.com/news/GLUE/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-620dbf2c
Ticker: GLUE
Company: Monte Rosa Therapeutics
Source: Monte Rosa Therapeutics
Published: 2026-05-20 11:00 EST
## Summary

Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced th...

## Article Body
Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences:

TD Cowen 7 th Annual Oncology Innovation Summit (virtual) – fireside chat, May 27, 2026, at 12:00 p.m. ET

Jefferies Global Healthcare Conference in New York – fireside chat, June 4, 2026, at 11:40 a.m. ET

Webcasts of the fireside chats will be accessible via the “Events & Presentations” section of Monte Rosa’s website at ir.monterosatx.com , and archived versions will be made available for 30 days following the presentations.

About Monte Rosa Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry’s leading pipeline of first-in-class and only-in-class MGDs, spanning autoimmune and inflammatory diseases, oncology, and beyond, with three programs in the clinic. Monte Rosa has ongoing collaborations with leading pharmaceutical companies in the areas of immunology, oncology and neurology. For more information, visit www.monterosatx.com .

Investors Andrew Funderburk ir@monterosatx.com

Media Cory Tromblee, Scient PR media@monterosatx.com
## Recent Company News
- 2026-07-02 20:01 EST — [Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/GLUE/monte-rosa-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bc49cd8f) — Source: Monte Rosa Therapeutics
- 2026-06-02 20:01 EST — [Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/GLUE/monte-rosa-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-e01d3eb4) — Source: Monte Rosa Therapeutics
- 2026-05-20 11:00 EST — [Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/GLUE/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-620dbf2c) — Source: Monte Rosa Therapeutics
- 2026-05-07 11:00 EST — [Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates](https://biopharmsignal.com/news/GLUE/monte-rosa-therapeutics-announces-first-quarter-2026-financial-results-and-busin-705bfd4d) — Source: Monte Rosa Therapeutics
- 2026-05-05 20:01 EST — [Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/GLUE/monte-rosa-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-68df4851) — Source: Monte Rosa Therapeutics
## Related News
- 2026-07-28 20:15 EST — BDX — [BD Board Declares Dividend](https://biopharmsignal.com/news/BDX/bd-board-declares-dividend-ea66eb4a)
- 2026-07-28 13:00 EST — ENLV — [Enlivex Announces $400,000,000 Private Placement](https://biopharmsignal.com/news/ENLV/enlivex-announces-400-000-000-private-placement-20e71a7a)
- 2026-07-28 12:30 EST — XRAY — [Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship](https://biopharmsignal.com/news/XRAY/dentsply-sirona-advances-commercial-growth-strategy-in-canada-through-expanded-m-e2440bb2)
- 2026-07-28 12:30 EST — RLMD — [Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-appoints-uro-oncology-leader-bipin-dalmia-as-chief-business-5c4d7b11)
- 2026-07-28 12:05 EST — RIGL — [Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2026-financ-5b987d7a)